<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02265003</url>
  </required_header>
  <id_info>
    <org_study_id>Anaemie</org_study_id>
    <secondary_id>14-016</secondary_id>
    <nct_id>NCT02265003</nct_id>
  </id_info>
  <brief_title>Red Blood Cells as a Reflection of Endothelial Function in Old Age</brief_title>
  <official_title>Red Blood Cells as a Reflection of Endothelial Function in Old Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to find out, how far red blood cells reflect age-depended changes in
      endothelial function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It will be investigated with determination of endothelial function (measured as flow-mediated
      vasodilation) and of circulated nitric oxid-pool in red blood cells and in blood plasma, how
      far red blood cells reflect age-depended changes in endothelial function.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of endothelial function</measure>
    <time_frame>baseline</time_frame>
    <description>measured as flow-mediated vasodilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of nitric oxide(NO)-pool in red blood cells and blood plasma</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of erythrocytes parameter</measure>
    <time_frame>baseline</time_frame>
    <description>It will be determinated: oxidative status, signalling of nitric oxide, function, creation, amount and aging of red blood cells, cell-to-cell-interaction, microRNA and inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Parameter</measure>
    <time_frame>baseline</time_frame>
    <description>It will be determinated: hemodynamic, microcirculation and physicomechanic</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Red Blood Cells</condition>
  <condition>Endothelial Function</condition>
  <condition>Nitric Oxide Pool in Red Blood Cells and Blood Plasma</condition>
  <arm_group>
    <arm_group_label>Healthy young age</arm_group_label>
    <description>Healthy subjects in age of 18-35 years, without cardiac dysrhythmia, hypertension, diabetes mellitus, acute inflammations and terminal kidney disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy middle age</arm_group_label>
    <description>Healthy subjects in age of 35-45 years, without cardiac dysrhythmia, hypertension, diabetes mellitus, acute inflammations and terminal kidney disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy old</arm_group_label>
    <description>Healthy subjects in age of &gt;70 years, without cardiac dysrhythmia, hypertension, diabetes mellitus, acute inflammations and terminal kidney disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Patients with atherosclerosis</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        4 groups:

          -  healthy young aged 18-35 years (30 subjects)

          -  healthy middel aged 35-45 years (30 subjects)

          -  healthy old aged &gt; 70 years (30 subjects)

          -  patients (50 subjects)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Groups 1-3:

        Inclusion Criteria:

          -  healthy subjects

          -  informed consent

        Exclusion Criteria:

          -  hypertension (blood pressure ≥140/90 mmHg),

          -  hypercholesterolemia (LDL ≥250 mg/dl, HDL ≤45 mg/dl),

          -  diabetes mellitus (fasting plasma glucose ≥128 mg/dl)

          -  acute inflammation (CRP &gt;0.5 mg/dl)

          -  malignant diseases

          -  heart failure (NYHA III-IV)

          -  arrhythmia of high degree

          -  acute or terminated kidney disease

          -  cardiovascular diseases ( cardiac artery disease, peripheral vascular disease and
             cerebrovascular diseases)

          -  anemia

          -  pregnancy

        Group 4 :

        Inclusion Criteria:

          -  angiographical signs of apparent atherosclerosis (cardiac artery disease or peripheral
             vascular disease or degenerative valvular heart disease)

          -  informed consent

        Exclusion Criteria:

          -  Hypertension (blood pressure ≥140/90 mmHg),

          -  Hypercholesterolemia (LDL ≥250 mg/dl, HDL ≤45 mg/dl),

          -  Diabetes mellitus (fasting plasma glucose ≥128 mg/dl)

          -  acute inflammation (CRP &gt;0.5 mg/dl)

          -  malignant diseases

          -  heart failure (NYHA III-IV)

          -  arrhythmia of high degree

          -  acute or terminated kidney disease

          -  cardiovascular diseases ( cardiac artery disease, peripheral vascular disease and
             cerebrovascular diseases)

          -  anemia

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malte Kelm, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Pneumology and Angiology, University Hospital Duesseldorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miriam Miriam Cortese-Krott, PhD</last_name>
    <email>Miriam.Cortese@uni-duesseldorf.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Georg Wolff</last_name>
    <email>Georg.Wolff@med.uni-duesseldorf.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Duesseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Cortese-Krott, PhD</last_name>
      <email>Miriam.Cortese@uni-duesseldorf.de</email>
    </contact>
    <contact_backup>
      <last_name>Georg Wolff</last_name>
      <email>Georg.Wolff@med.uni-duesseldorf.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2014</study_first_submitted>
  <study_first_submitted_qc>October 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2014</study_first_posted>
  <last_update_submitted>October 19, 2016</last_update_submitted>
  <last_update_submitted_qc>October 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>red blood cells</keyword>
  <keyword>endothelial function</keyword>
  <keyword>nitric oxide pool in red blood cells</keyword>
  <keyword>nitric oxide poll in blood plasma</keyword>
  <keyword>nitric oxide synthase III - expression</keyword>
  <keyword>oxidative status</keyword>
  <keyword>nitric oxide signalling</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

